World association for the advancement of veterinary parasitology (WAAVP): Third edition of guideline for evaluating the efficacy of equine anthelmintics.

This guideline have been developed to assist in the design, execution, and interpretation of studies to assess the efficacy of anthelmintic drugs against internal parasites of equines, including nematodes, cestodes, and larval instars of Gasterophilus spp. The design and execution of critical and controlled studies are outlined, and their advantages and disadvantages are discussed. Unique considerations for specific target parasites are included. Information is also provided on selection of animals, procedures for randomization, housing, feeding, dosage titration, dosage confirmation and field studies, record keeping and necropsy procedures. Finally, this document includes guidance for group size determination and statistical analysis of study results. This guideline should assist investigators in the evaluation of anthelmintic drugs in horses by using comparable and standardized procedures in studies with appropriate numbers of animals.

New Perspectives in Equine Intestinal Parasitic Disease: Insights in Monitoring Helminth Infections.

Regular anthelmintic treatment has contributed to anthelmintic resistance in horse helminths. This mass anthelmintic treatment was originally developed owing to a lack of larvicidal drugs against Strongylus vulgaris. The high prevalence of anthelmintic resistance and shortening of strongyle egg reappearance period after avermectins/moxidectins requires epidemiologically appropriate and sustainable measures. Selective anthelmintic treatment is a much-needed deworming approach: More than 50% of adult horses manifest no strongyle egg excretion. In this article, selective anthelmintic treatment procedure is described, with the specific focus on the advantages of an evidence-based, medically appropriate, and sustainable treatment system that slows the development of anthelmintic resistance.

Decreased strongyle egg re-appearance period after treatment with ivermectin and moxidectin in horses in Belgium, Italy and The Netherlands.

The objective of the present study was to evaluate the efficacy of an oral treatment with ivermectin (IVM) or moxidectin (MOX) against gastro-intestinal strongyles in naturally infected horses by performing a faecal egg count reduction test (FECRT) and by monitoring the egg reappearance period (ERP) after treatment. Therefore, a field efficacy study with a randomised complete block design for each study site was conducted, with the individual animal as the experimental unit. At least 10 study sites in Italy, Belgium and The Netherlands were selected and animals were allocated to one of the two treatment groups based on the pre-treatment faecal egg counts (FEC). Animals were treated on Day 0 with an oral paste containing either IVM (at 0.2mg/kg bodyweight) or MOX (at 0.4 mg/kg bodyweight). After treatment, faecal samples were collected at least every fortnight during 56 days after treatment with IVM and during 84 days after MOX treatment. In total, 320 horses on 32 farms were examined. The FECRT on Day 14 indicated a 100% efficacy in 59 of the 64 treatment groups and >92% efficacy in the remaining 5 groups. The ERP was decreased for at least one of the anthelmintics on 17 out of 32 study sites (15 sites or 47% for MOX and 17 sites or 53% for IVM) and on 9 sites (28%) the ERP was decreased for both anthelmintics. On some of these study sites the efficacy declined at the end of the expected ERP, often with good efficacy 2 weeks earlier. Nevertheless, on 1, 3 and 5 study sites in Italy, Belgium and The Netherlands respectively, an efficacy below 90% for IVM and MOX was identified as soon as Day 42 or Day 56. In The Netherlands, the efficacy of IVM was below 90% from Day 28 or Day 35 after treatment on 1 site each. The present study reports a high efficacy of MOX and IVM in a FECRT 14 days after treatment, yet does indicate a shortened ERP for these treatments in more than half of the selected study sites.

Autochthonous Angiostrongylus vasorum infection in dogs in The Netherlands.

Until recently, autochthonous infections with Angiostrongylus vasorum were not thought to occur in The Netherlands. However, in 2007 four dogs were diagnosed with angiostrongylosis. Three of them had never left the country. Subsequently, faecal samples from 485 dogs living in the same region where the positive dogs had been diagnosed in 2007 were collected through veterinarians, hunting associations and kennels between January and April 2008. A. vasorum larvae were found in faecal samples of four dogs. Three of those had never been outside the country. Though only few samples were found positive, A. vasorum is now considered autochthonous in The Netherlands.